{"id":"placebo-and-peginterferon","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"30-50","effect":"Headache"},{"rate":"20-40","effect":"Neutropenia"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression / mood changes"},{"rate":"5-15","effect":"Injection site reactions"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo and peginterferon","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:50:05.395442+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:50:29.784049+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:50:11.830675+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo and peginterferon","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:50:12.614714+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interferon alpha/beta receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:50:18.307763+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201560/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:50:18.216727+00:00"}},"_dailymed":null,"aiSummary":"Placebo and peginterferon, marketed by National Taiwan University Hospital, holds a niche position in the therapeutic landscape. The key composition patent is set to expire in 2028, providing a period of exclusivity and potential revenue protection. However, the lack of specified primary indication and key trial results poses a significant risk in understanding and communicating the drug's efficacy and market relevance.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peginterferon alfa binds to interferon-alpha receptors on cell surfaces, activating JAK-STAT signaling pathways that induce antiviral and antiproliferative gene expression. The pegylation extends the drug's half-life, allowing for less frequent dosing while maintaining therapeutic efficacy. This combination study appears to compare peginterferon against placebo, likely in a viral hepatitis or similar infectious disease context.","oneSentence":"Peginterferon is a long-acting interferon alpha conjugated with polyethylene glycol that enhances antiviral and immunomodulatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:35.787Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:50:29.784404+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Chronic hepatitis C (likely, based on peginterferon use in marketed formulations)"},{"name":"Chronic hepatitis B (possible)"}]},"trialDetails":[{"nctId":"NCT06144697","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2024-01-29","conditions":"Healthy Participants","enrollment":267},{"nctId":"NCT06544551","phase":"PHASE3","title":"Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Beijing Kawin Technology Share-Holding Co., Ltd.","startDate":"2021-12-28","conditions":"Chronic Hepatitis B Virus Infection","enrollment":336},{"nctId":"NCT05244057","phase":"PHASE2","title":"A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2022-08-23","conditions":"Chronic Hepatitis B","enrollment":8},{"nctId":"NCT01353911","phase":"PHASE2","title":"Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":368},{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT04183491","phase":"PHASE1","title":"Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-02-28","conditions":"Healthy Subjects, Pharmacokinetics, Pharmacodynamics","enrollment":84},{"nctId":"NCT04354259","phase":"PHASE2","title":"Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-05-13","conditions":"Sars-CoV2, Covid-19","enrollment":157},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT03870763","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants","status":"TERMINATED","sponsor":"Biogen","startDate":"2019-03-19","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":11},{"nctId":"NCT04079088","phase":"PHASE2","title":"Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2021-06-30","conditions":"Relapsing Multiple Sclerosis","enrollment":""},{"nctId":"NCT03719313","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2018-12-01","conditions":"Hepatitis Delta Virus","enrollment":407},{"nctId":"NCT04344600","phase":"PHASE2","title":"Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2020-06-29","conditions":"Sars-CoV-2 Infection","enrollment":6},{"nctId":"NCT04967430","phase":"PHASE3","title":"TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-08-27","conditions":"Sars-CoV2, Covid19","enrollment":763},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT00166296","phase":"PHASE2","title":"Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-03","conditions":"Major Depressive Disorder, Hepatitis C, Chronic","enrollment":133},{"nctId":"NCT03387046","phase":"PHASE2","title":"A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-03-26","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":7},{"nctId":"NCT02908191","phase":"PHASE1","title":"A Study in Healthy Volunteers and Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":86},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT00100659","phase":"PHASE3","title":"PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-12","conditions":"Chronic Hepatitis C","enrollment":114},{"nctId":"NCT01370642","phase":"PHASE3","title":"Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":294},{"nctId":"NCT00704405","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03-27","conditions":"Hepatitis C, Chronic","enrollment":285},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT03272009","phase":"PHASE1","title":"Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects","status":"COMPLETED","sponsor":"Enyo Pharma","startDate":"2017-09-21","conditions":"Hepatitis B, Chronic","enrollment":73},{"nctId":"NCT03109730","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2017-06-15","conditions":"Chronic Hepatitis B","enrollment":38},{"nctId":"NCT01314261","phase":"PHASE2","title":"Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-03","conditions":"Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection","enrollment":37},{"nctId":"NCT01439373","phase":"PHASE2","title":"Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-07","conditions":"Hepatitis C, Chronic","enrollment":16},{"nctId":"NCT02401737","phase":"PHASE1","title":"Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients","status":"COMPLETED","sponsor":"Novira Therapeutics, Inc.","startDate":"2015-01-31","conditions":"Chronic Hepatitis B","enrollment":58},{"nctId":"NCT02112799","phase":"PHASE1","title":"Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients","status":"COMPLETED","sponsor":"Novira Therapeutics, Inc.","startDate":"2014-04-30","conditions":"Chronic Hepatitis B","enrollment":55},{"nctId":"NCT03125213","phase":"PHASE2","title":"A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects","status":"WITHDRAWN","sponsor":"Alios Biopharma Inc.","startDate":"2017-09-12","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT01265511","phase":"PHASE2","title":"Study of SCY-635, Pegasys and Copegus in Hepatitis C","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2010-11","conditions":"Hepatitis C Infection","enrollment":10},{"nctId":"NCT01890200","phase":"PHASE3","title":"The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)","status":"WITHDRAWN","sponsor":"TCM Biotech International Corp.","startDate":"2015-06","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT01482390","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-30","conditions":"Hepatitis C","enrollment":80},{"nctId":"NCT01153919","phase":"PHASE2","title":"Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2010-06-30","conditions":"Hepatitis C Infection, Thrombocytopenia","enrollment":27},{"nctId":"NCT00959699","phase":"PHASE2","title":"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"HIV Infections, Hepatitis C, HCV Infection","enrollment":99},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00845065","phase":"PHASE3","title":"Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02","conditions":"Hepatitis C, Chronic","enrollment":202},{"nctId":"NCT00705432","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":1472},{"nctId":"NCT00978497","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-09","conditions":"HCV Infection","enrollment":97},{"nctId":"NCT01903954","phase":"PHASE2","title":"A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-01","conditions":"Hepatitis C, Chronic","enrollment":283},{"nctId":"NCT01278134","phase":"PHASE2","title":"A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":170},{"nctId":"NCT00963885","phase":"PHASE2","title":"A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Hepatitis C, Chronic","enrollment":229},{"nctId":"NCT01185860","phase":"PHASE1","title":"A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Hepatitis C, Chronic","enrollment":59},{"nctId":"NCT01318694","phase":"PHASE3","title":"Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2011-03","conditions":"Hepatitis C","enrollment":1081},{"nctId":"NCT01183169","phase":"PHASE2","title":"Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2010-08","conditions":"Hepatitis C","enrollment":459},{"nctId":"NCT02716779","phase":"PHASE2","title":"Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Hepatitis C, Chronic","enrollment":68},{"nctId":"NCT01482403","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":58},{"nctId":"NCT01485991","phase":"PHASE3","title":"TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-02","conditions":"Hepatitis C","enrollment":771},{"nctId":"NCT02568111","phase":"PHASE4","title":"Brimonidine Tartrate for the Treatment of Injection Related Erythema","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2016-02","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS)","enrollment":""},{"nctId":"NCT00077649","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Hepatitis C, Chronic","enrollment":188},{"nctId":"NCT01323244","phase":"PHASE3","title":"A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-12","conditions":"Hepatitis C","enrollment":142},{"nctId":"NCT00854802","phase":"NA","title":"A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2009-01","conditions":"Chronic Hepatitis C","enrollment":290},{"nctId":"NCT01728324","phase":"PHASE3","title":"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-11","conditions":"Hepatitis C, Chronic","enrollment":496},{"nctId":"NCT01257204","phase":"PHASE2","title":"Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12","conditions":"Hepatitis C Virus","enrollment":196},{"nctId":"NCT01425970","phase":"PHASE2","title":"Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C","enrollment":210},{"nctId":"NCT01125189","phase":"PHASE2","title":"Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-07","conditions":"Hepatitis C Virus","enrollment":558},{"nctId":"NCT00874770","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-06","conditions":"Hepatitis C Infection","enrollment":74},{"nctId":"NCT01170962","phase":"PHASE2","title":"Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":512},{"nctId":"NCT01016912","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis C Infection","enrollment":51},{"nctId":"NCT01448044","phase":"PHASE3","title":"Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C","enrollment":152},{"nctId":"NCT01309932","phase":"PHASE2","title":"Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"Hepatitis C","enrollment":165},{"nctId":"NCT01193361","phase":"PHASE2","title":"Ph IIA Study (SOC +/- NS5B)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-10","conditions":"Hepatitis C Virus","enrollment":39},{"nctId":"NCT01616524","phase":"PHASE3","title":"Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus (HCV)","enrollment":880},{"nctId":"NCT01030432","phase":"PHASE2","title":"Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-02","conditions":"Hepatitis C Virus","enrollment":285},{"nctId":"NCT01017575","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis C Infection","enrollment":55},{"nctId":"NCT01725529","phase":"PHASE3","title":"An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-11","conditions":"Hepatitis C, Chronic","enrollment":457},{"nctId":"NCT00633230","phase":"PHASE1","title":"Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"","conditions":"Hepatitis C Virus","enrollment":""},{"nctId":"NCT01011166","phase":"PHASE2","title":"Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Chronic Hepatitis C Infection","enrollment":81},{"nctId":"NCT01081158","phase":"PHASE1","title":"Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Hepatitis C, Chronic","enrollment":41},{"nctId":"NCT01371604","phase":"PHASE2","title":"Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":68},{"nctId":"NCT01074008","phase":"PHASE2","title":"A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":"Hepatitis C, HCV, Chronic Hepatitis C Infection","enrollment":74},{"nctId":"NCT01197157","phase":"PHASE2, PHASE3","title":"Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients","status":"COMPLETED","sponsor":"National Liver Institute, Egypt","startDate":"2010-09","conditions":"Hepatitis C","enrollment":200},{"nctId":"NCT00906399","phase":"PHASE3","title":"Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-06","conditions":"Relapsing Multiple Sclerosis","enrollment":1516},{"nctId":"NCT00323804","phase":"PHASE2, PHASE3","title":"Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2006-05","conditions":"Hepatitis C, Chronic, Liver Fibrosis","enrollment":372},{"nctId":"NCT00627926","phase":"PHASE3","title":"A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2008-03","conditions":"Hepatitis C","enrollment":1095},{"nctId":"NCT00556504","phase":"PHASE2","title":"The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection","status":"COMPLETED","sponsor":"TCM Biotech International Corp.","startDate":"2007-07","conditions":"Chronic Hepatitis C","enrollment":84},{"nctId":"NCT00420784","phase":"PHASE2","title":"A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-02","conditions":"Hepatitis C","enrollment":465},{"nctId":"NCT00372385","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-08","conditions":"Chronic Hepatitis C","enrollment":334},{"nctId":"NCT00336479","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-06","conditions":"Chronic Hepatitis C","enrollment":263},{"nctId":"NCT00441103","phase":"PHASE3","title":"A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2006-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":180},{"nctId":"NCT00882908","phase":"PHASE2","title":"A Study of TMC435 in Combination With Pegylated Interferon Alp\\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-06","conditions":"Hepatitis C","enrollment":386},{"nctId":"NCT01290679","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-03","conditions":"Hepatitis C","enrollment":393},{"nctId":"NCT00980330","phase":"PHASE2","title":"A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-10","conditions":"Hepatitis C","enrollment":463},{"nctId":"NCT01289782","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":395},{"nctId":"NCT00561353","phase":"PHASE2","title":"A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT00495391","phase":"PHASE2","title":"Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2007-07","conditions":"Chronic Hepatitis C","enrollment":64},{"nctId":"NCT01281839","phase":"PHASE3","title":"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":394},{"nctId":"NCT01188772","phase":"PHASE2","title":"Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":147},{"nctId":"NCT01054729","phase":"PHASE2","title":"Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-01","conditions":"Hepatitis C","enrollment":64},{"nctId":"NCT00911963","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2009-04","conditions":"Hepatitis C","enrollment":49},{"nctId":"NCT01371578","phase":"PHASE2","title":"Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":163},{"nctId":"NCT00637923","phase":"PHASE2","title":"Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2008-03","conditions":"Chronic Hepatitis C","enrollment":112},{"nctId":"NCT01504581","phase":"PHASE1","title":"Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2011-03","conditions":"Healthy","enrollment":48},{"nctId":"NCT01271790","phase":"PHASE2","title":"A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-10","conditions":"Hepatitis C, Chronic","enrollment":245},{"nctId":"NCT01356160","phase":"PHASE2","title":"GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":351},{"nctId":"NCT01225380","phase":"PHASE2","title":"A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-10","conditions":"Chronic Hepatitis C Infection","enrollment":324},{"nctId":"NCT00703118","phase":"PHASE3","title":"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-10","conditions":"Hepatitis C, Chronic","enrollment":663},{"nctId":"NCT01292239","phase":"PHASE3","title":"A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":183},{"nctId":"NCT01797848","phase":"PHASE3","title":"Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2014-06","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00743795","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-10","conditions":"HCV Infection","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1201560"},"_approvalHistory":[],"publicationCount":183,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo 0.5 mg/day po at week 1-4","Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52"],"phase":"marketed","status":"active","brandName":"Placebo and peginterferon","genericName":"Placebo and peginterferon","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:50:29.784404+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}